Bloomberg FIT Breaks $1 Trillion in OTC Derivative Volume
Bloomberg readies for 2011 launch of Swaps Execution Facility
Bloomberg Fixed-Income Trading executives today announced that they have broken through the $1 trillion mark in electronically traded interest-rate swaps and credit default swaps for 2011.
More than 16,000 trades have been executed on Bloomberg's Fixed-Income Trading (FIT) platform so far this year, with 23 dealers and more than 450 buy-side participants, representing a 50 percent increase in fixed income trading volume over the last year.
"We are setting record-breaking volumes and experiencing remarkable growth, thanks to strong participation from an extensive list of buy-side and sell-side participants," said Ben Macdonald, Bloomberg Global Head of Fixed-Income. "This success positions us well to be the industry's leading Swap Execution Facility."
Bloomberg intends to register with the U.S. Commodity Futures Trading Commission (CFTC) and the U.S. Securities and Exchange Commission (SEC) as a Swap Execution Facility (SEF) and Security Based Swap Execution Facility (SBSEF) respectively, as required by the Dodd-Frank Act. “Our electronic trading tools for over-the-counter derivatives and central clearing links will be the backbone of our SEF offering,” Macdonald said. "Meanwhile, we are still seeing strong growth in our voice confirmation trading (VCON)."
Building on Bloomberg’s Central Counterparty Connectivity Launch in 2009, all trades executed on Bloomberg FIT can be routed directly to CME Clearing, the IntercontinentalExchange (ICE), the International Derivatives Clearing Group (IDCG) and LCH. Clearnet Ltd.
Bloomberg now has 23 liquidity providers active for IRS trading, and 11 dealers live for CDS trading. Following the partnership and initial launch of IRS trading with Barclays Capital’s BARX platform in 2003, additional dealers participating on FIT include: BBVA, BNP Paribas, BofA Merrill Lynch, Credit Agricole CIB, Citigroup, Commerzbank, Credit Suisse, Danske Bank, Deutsche Bank, Goldman Sachs, HSBC, J.P. Morgan, Morgan Stanley, Natixis, Nomura Securities International, RBS, Société Générale, Standard Chartered, UBS and West LB.
Following the partnership and initial launch of CDS indices trading with J.P. Morgan’s JPTE Platform in 2009, the additional CDS dealers participating on FIT are: BNP Paribas, Barclays Capital, BofA Merrill Lynch, Citigroup, Credit Suisse, Deutsche Bank, Goldman Sachs, Morgan Stanley, RBS and UBS.
For a demonstration of e-trading of derivatives on FIT, type SEF<GO> on the Bloomberg Professional® service or contact Jeff Missimer at 212-617-2236 or at jmissimer@bloomberg.net ; in Europe or Asia please contact Richard Warrick at +44-20-7330-7604 or at rwarrick@bloomberg.net .
About Bloomberg
Bloomberg is the world’s most trusted source of information for financial professionals and businesses. Bloomberg combines innovative technology with unmatched analytics, data, news, and display and distribution capabilities, to deliver critical information via the Bloomberg Professional® service and multimedia platforms, including Bloomberg Businessweek and Bloomberg Markets magazines. Bloomberg's media properties span television, radio, digital and print, making up one of the world’s largest news organizations. Headquartered in New York, the company employs more than 12,900 people in 166 locations around the world. For more information go to www.bloomberg.com .
Contact:
Media Contacts:
Bloomberg LP
Pam Snook, +212-617-7652
pamsnook@bloomberg.net
or
Cognito
- US
Sophie Fischman, +1-646-395-6300
Bloomberg@cognitomedia.com
or
EMEA
Stuart
Macaulay, +44 20 7438 1100
BloombergEMEA@cognitomedia.com
or
APAC
Anne
Karumo, +65 8112 64 09
BloombergAsia@cognitomedia.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom